Cardiff Oncology Stock Investor Sentiment

CRDF Stock  USD 2.59  0.07  2.63%   
Roughly 86 percent of Cardiff Oncology's stockholders are aggressively looking to sell. The analysis of the overall investor sentiment regarding Cardiff Oncology suggests that a large number of traders are panicking. The current market sentiment, together with Cardiff Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Cardiff Oncology stock news signals to limit their universe of possible portfolio assets.
  

Cardiff Oncology Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Cardiff Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two weeks ago at finance.yahoo.com         
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutate...
Yahoo News
over two weeks ago at gurufocus.com         
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS ...
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
HC Wainwright Cuts Cardiff Oncology Price Target to 13.00
news
over three weeks ago at news.google.com         
HC Wainwright Has Lowered Expectations for Cardiff Oncology Stock Price - MarketBeat
Google News at Macroaxis
over three weeks ago at zacks.com         
Cardiff Oncology Reports Q3 Loss, Tops Revenue Estimates
zacks News
over three weeks ago at finance.yahoo.com         
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
Yahoo News
over three weeks ago at finance.yahoo.com         
Cardiff Oncology Q3 Earnings Snapshot
Yahoo News
over a month ago at news.google.com         
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Se...
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Experts Gather at CEPT University for Symposium on Leveraging Earth Observation Technologies
Yahoo News
over a month ago at gurufocus.com         
Cardiff Oncology Inc Q2 2024 Earnings Call Highlights Strategic Trials and Financial ...
Gurufocus Stories at Macroaxis
over a month ago at simplywall.st         
Were Keeping An Eye On Cardiff Oncologys Cash Burn Rate
Simply Wall St News at Macroaxis
over two months ago at news.google.com         
Cardiff Oncology Paramount Data Imminent In Huge First-Line mCRC Market - Seeking Alpha
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Pace Gary W of 29700 shares of Cardiff Oncology at 2.33 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Jacob Gary S of 223 shares of Cardiff Oncology at 516.96 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Cardiff Oncology, Inc. Sees Significant Growth in Short Interest - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Cardiff Oncology that are available to investors today. That information is available publicly through Cardiff media outlets and privately through word of mouth or via Cardiff internal channels. However, regardless of the origin, that massive amount of Cardiff data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cardiff Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cardiff Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cardiff Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cardiff Oncology alpha.

Cardiff Oncology Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Jacob Gary S of 223 shares of Cardiff Oncology at 516.96 subject to Rule 16b-3
09/13/2024
2
Acquisition by Pace Gary W of 29700 shares of Cardiff Oncology at 2.33 subject to Rule 16b-3
10/01/2024
3
Cardiff Oncology Inc Q2 2024 Earnings Call Highlights Strategic Trials and Financial ...
10/09/2024
4
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
11/07/2024
5
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS ...
11/19/2024

Complementary Tools for Cardiff Stock analysis

When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk